| Identification | Back Directory | [Name]
Dexamethasone EP Impurity E | [CAS]
13209-41-1 | [Synonyms]
Dexamethasone EP Imp E
Dexamethasone impurity E
Dexamethasone Impurity L
(8S,10S,13S,14S,16R,17R)-17-hydroxy
16α-Methyl-9,11-dehydro Prednisolone
Dexamethasone Impurity 5(Dexamethasone EP Impurity E)
17,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione
17, 21-dihydroxy-16α-methylpregna- 1, 4, 9(11)-triene-3,20-dione
(16α)-17,21-Dihydroxy-16-Methylpregna-1,4,9(11)-triene-3,20-dione
17.alpha.,21-Dihydroxy-16.alpha.-methylpregna-1,4,9(11)-triene-3,20-dione
(8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one
((2R,3R,4aS,4bS,10aS,10bR,11S,12aS)-10b-fluoro-2,11-dihydroxy-3,10a,12a-trimethyl-1,8-dioxo-1,2,3,4,4a,4b,5,6,8,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl)methyl dihydrogen phosphate | [EINECS(EC#)]
236-177-8 | [Molecular Formula]
C22H28O4 | [MDL Number]
MFCD18452727 | [MOL File]
13209-41-1.mol | [Molecular Weight]
356.46 |
| Chemical Properties | Back Directory | [Melting point ]
228-231 °C(Solv: acetone (67-64-1); hexane (110-54-3)) | [Boiling point ]
548.3±50.0 °C(Predicted) | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
Chloroform (Slightly), Dioxane (Slightly), Ethyl Acetate (Slightly) | [form ]
Solid | [pka]
12.53±0.70(Predicted) | [color ]
Pale Yellow | [InChIKey]
ZYTXTXAMMDTYDQ-JBFVNPOPNA-N | [SMILES]
C1(=O)C=C2[C@](C)(C=C1)C1[C@]([H])([C@@]3([H])[C@@](CC=1)(C)[C@@](O)(C(=O)CO)[C@H](C)C3)CC2 |&1:4,9,11,13,17,23,r| |
| Hazard Information | Back Directory | [Uses]
A related intermediate of Prednisolone (P703740). | [Biological Activity]
Vamorolonea synthetic steroidis an orally available dissociative steroid with anti-inflammatory efficacy. It is a partial agonist of the glucocorticoid receptor (NR3C1) th at appear to be safe and well tolerated. Alsovamorolone is a potent antagonist of the mineralocorticoid receptor (NR3C2). It is under development for children with Duchenne muscular dystrophy. | [in vivo]
Vamorolone (5-30 mg/kg; cherry syrup) shows a superior side effect profile compared to pharmacological glucocorticoids in mdx mice[1].
?
Vamorolone (30 mg/kg; orally; daily for 20 days) reduces CNS Inflammation in murine experimental autoimmune encephalomyelitis[2]. | Animal Model: | C57BL/6 mice (experimental autoimmune encephalomyelitis)[2] | | Dosage: | 30 mg/kg | | Administration: | Orally; daily for 20 days (starting one day prior to MOG 33-55 peptide immunization and continuing) | | Result: | Reduced CNS inflammation in murine experimental autoimmune encephalomyelitis. |
| [storage]
Store at -20°C | [Toxics Screening Level]
The ITSL for 17, 21-dihydroxy-16 alpha-methylpregna-1,4,9 (11)-triene-3, 20-dione has been changed from 0.04 μg/m3 to 0.1 μg/m3 based on annual averaging time. |
|
|